Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis

Cancer statistics, 2020

(2020) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway

(2020) Shuang Zhao et al.   LIFE SCIENCES

B cells are associated with survival and immunotherapy response in sarcoma

(2020) Florent Petitprez et al.   NATURE

Optimizing Patient Outcomes with PD‐1/PD‐L1 Immune Checkpoint Inhibitors for the First‐Line Treatment of Advanced Non–Small Cell Lung Cancer

(2020) Ninh M. La‐Beck et al.   PHARMACOTHERAPY

Natural Product Evodiamine with Borate Trigger Unit: Discovery of Potent Antitumor Agents against Colon Cancer

(2020) Xinglin Li et al.   ACS Medicinal Chemistry Letters

Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma

(2020) Elena Galvani et al.   Nature Communications

MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer

(2020) Yota Yasumizu et al.   Nature Communications

Evodiamine Inhibits Lipopolysaccharide (LPS)-Induced Inflammation in BV-2 Cells via Regulating AKT/Nrf2-HO-1/NF-κB Signaling Axis

(2020) Tianyu Meng et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Evodiamine Exerts Anticancer Effects Against 143B and MG63 Cells Through the Wnt/β-Catenin Signaling Pathway

(2020) Shengdong Yang et al.   Cancer Management and Research

Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape

(2019) Xianjie Jiang et al.   Molecular Cancer

A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of non-immunogenic tumors to allow T cell-mediated anticancer activity

(2019) Hayley S. Ma et al.   Cancer Immunology Research

Tumor-infiltrating CD8+ T-cell density is an independent prognostic marker for oral squamous cell carcinoma

(2019) Shota Shimizu et al.   Cancer Medicine

The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer

(2019) Jong Woo Lee et al.   Journal of Thoracic Oncology

ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment

(2019) Magnus T. Dillon et al.   CLINICAL CANCER RESEARCH

MUC1-C INTEGRATES CHROMATIN REMODELING AND PARP1 ACTIVITY IN THE DNA DAMAGE RESPONSE OF TRIPLE-NEGATIVE BREAST CANCER CELLS

(2019) Masaaki Yamamoto et al.   CANCER RESEARCH

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy

(2019) Tuba N. Gide et al.   CANCER CELL

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

(2019) Filipe Martins et al.   Nature Reviews Clinical Oncology

Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment

(2019) Pulak Ranjan Nath et al.   Cancer Immunology Research

Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non–Small Cell Lung Cancer

(2019) Joshua M. Bauml et al.   JAMA Oncology

Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer

(2019) Jun Lu et al.   BMC CANCER

Rewiring regulatory T cells for tumour killing

(2019) Tomasz Maj et al.   Nature Biomedical Engineering

Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups

(2019) Lawrence P. Andrews et al.   NATURE IMMUNOLOGY

Tissue-resident memory CD8+ T cells amplify anti-tumor immunity by triggering antigen spreading through dendritic cells

(2019) Evelyn Menares et al.   Nature Communications

Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

(2019) José Medina-Echeverz et al.   Nature Communications

PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways

(2019) Yunlong Zhao et al.   IMMUNITY

Latest developments in MUC1 immunotherapy

(2018) Joyce Taylor-Papadimitriou et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect

(2018) Chenlu Liu et al.   IMMUNOLOGY LETTERS

High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy

(2018) Carsten Krieg et al.   NATURE MEDICINE

Inhibition of MUC1-C entering nuclear suppresses MYC expression and attenuates malignant growth in esophageal squamous cell carcinoma

(2018) Zhongwei Xin et al.   OncoTargets and Therapy

Evodiamine, a Novel NOTCH3 Methylation Stimulator, Significantly Suppresses Lung Carcinogenesis in Vitro and in Vivo

(2018) Tao Su et al.   Frontiers in Pharmacology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Evodiamine inactivates NF-κB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo

(2018) Qi Guo et al.   OncoTargets and Therapy

Evodiamine prevents dextran sulfate sodium-induced murine experimental colitis via the regulation of NF-κB and NLRP3 inflammasome

(2018) Peng Shen et al.   BIOMEDICINE & PHARMACOTHERAPY

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

(2017) A R Pyzer et al.   LEUKEMIA

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

(2017) Marian L. Burr et al.   NATURE

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer

(2017) A Bouillez et al.   ONCOGENE

Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway

(2017) Xia Li et al.   PHARMACOLOGICAL RESEARCH

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model

(2017) Christelle Remy-Ziller et al.   Human Vaccines & Immunotherapeutics

Intratumoral CD8 + T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity

(2017) Brendan L. Horton et al.   Cancer Immunology Research

MUC1-C promotes the suppressive immune microenvironment in non-small cell lung cancer

(2017) Audrey Bouillez et al.   OncoImmunology

Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation

(2016) Elaine Lai-Han Leung et al.   ANTIOXIDANTS & REDOX SIGNALING

A novel alkaloid, evodiamine causes nuclear localization of cytochrome-c and induces apoptosis independent of p53 in human lung cancer cells

(2016) Vijay Mohan et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-κB Pathway in Colorectal Cancer

(2016) Hua Sui et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

(2016) Elisabeth Quoix et al.   LANCET ONCOLOGY

MUC1 Regulates Epithelial Inflammation and Apoptosis by PolyI:C through Inhibition of Toll/IL-1 Receptor-Domain–Containing Adapter-Inducing IFN-β (TRIF) Recruitment to Toll-like Receptor 3

(2014) Kosuke Kato et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

A signaling pathway consisting of miR-551b, catalase and MUC1 contributes to acquired apoptosis resistance and chemoresistance

(2014) Xiuling Xu et al.   CARCINOGENESIS

Pharmacological Actions of Multi-Target-Directed Evodiamine

(2013) Hui Yu et al.   MOLECULES

MUC1 and metastatic cancer

(2013) Teresa M. Horm et al.   Cell Adhesion & Migration

MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches

(2012) D W Kufe   ONCOGENE

Oncogenic function of the MUC1 receptor subunit in gene regulation

(2010) D Kufe   ONCOGENE